LOGIN  |  REGISTER
Recursion
Viking Therapeutics

Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference

March 07, 2023 | Last Trade: US$12.95 0.04 0.31

LANCASTER, Calif. / Mar 07, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually from March 13-15, 2023.

Shawn O’Connor, chief executive officer, will be presenting on Tuesday, March 14, 2023, at 11:20 a.m. Eastern Time, and he will be meeting with investors throughout the day. The live webcast can be accessed via this link and on the Investors page of the Simulations Plus website where it will also be available for replay after the event.

For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website or contact Brian Siegel from Hayden IR at This email address is being protected from spambots. You need JavaScript enabled to view it..

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page